Get the Stockscreener App
28.23
1.11%
0.31
After Hours:
28.30
0.07
+0.25%
Gh Research Plc stock is traded at $28.23, with a volume of 78,097.
It is up +1.11% in the last 24 hours and down -3.06% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$27.92
Open:
$27.86
24h Volume:
78,097
Relative Volume:
0.26
Market Cap:
$1.94B
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-35.74
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
+1.04%
1M Performance:
-3.06%
6M Performance:
+76.55%
1Y Performance:
+100.93%
1-Day Range:
$27.26
$28.31
1-Week Range:
$26.61
$28.33
52-Week Range:
$11.83
$31.44
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
28.23 | 1.97B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
Net margin % of GH Research Plc – HAM:1KA - TradingView
Net income before discontinued operations of GH Research Plc – HAM:1KA - TradingView
How Rising Losses And Milestone Spending At GH Research (GHRS) Have Changed Its Investment Story - simplywall.st
GHRS Q2 2026 Earnings: Narrower Loss of -$0.23 Per Share Beats Estimates by 25.6%Earnings Trend Analysis - vinanet.vn
Zacks Research Upgrades GH Research (NASDAQ:GHRS) to Hold - MarketBeat
RA Capital discloses 7.1% GH Research PLC (GHRS) stake in Schedule 13G/A - Stock Titan
Lynx1 Capital Management (NASDAQ: GHRS) reports 19.3% stake in GH Research - Stock Titan
GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
GH Research PLC Director Duncan Moore Granted 2,202 Share Options - Kalkine Media
GH Research PLC (GHRS) director receives 2,202 fully vested share options - Stock Titan
GH Research PLC (GHRS) director receives 2,202 options at $0.025 strike - Stock Titan
GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer - Stock Titan
GH Research (NASDAQ:GHRS) Sees Strong Trading VolumeShould You Buy? - MarketBeat
FY2026 EPS Estimates for GH Research Boosted by Analyst - MarketBeat
GH Research (GHRS) Retreats 2.4% to $29.53 as Clinical-Stage Biotech ConsolidatesFibonacci Entry Signals - vinanet.vn
Trading the Move, Not the Narrative: (GHRS) Edition - Stock Traders Daily
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates GH Research stock rating on FDA progress - Investing.com
Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative? - Sahm
GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen - MarketBeat
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com India
GH Research (NASDAQ:GHRS) Reaches New 12-Month High Following Earnings Beat - marketbeat.com
GH Research stock hits all-time high at 31.41 USD - Investing.com
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
GH Research PLC (GHRS) Stock Analysis: A Biotech Powerhouse with 30.55% Upside Potential - DirectorsTalk Interviews
GH Research PLC (GHRS) Stock News Today - TradingKey
GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GH Research (GHRS) Dips 1.21% to $30.27 Amid Clinical-Stage Biotech CautionTechnical Analysis Picks - vinanet.vn
GH Research PLC Stock 12‑Month Price Target Raised to $41.1, Implies 41% Upside - TradingView
Needham & Company LLC Raises GH Research (NASDAQ:GHRS) Price Target to $39.00 - MarketBeat
GH Research PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GHRS: GH001 achieves rapid, sustained TRD remission with fewer visits and robust IP protection - tradingview.com
GH Research (Nasdaq: GHRS) grows cash to $362.7M as R&D spending rises - Stock Titan
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development work - Bitget
GH Research (NASDAQ:GHRS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Is GH Research (GHRS) Trading At A Premium To Fair Value? - Yahoo Finance
Is GH Research (GHRS) Fully Valued Following Its Share Price Surge? - Sahm
(GHRS) Volatility Zones as Tactical Triggers - Stock Traders Daily
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected LossRevenue Surprise History - vinanet.vn
GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GH Research (NASDAQ:GHRS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
GHRS|GH Research PLC|Price:27.830|Chg%:+0.550 - TradingKey
GH Research PLC (GHRS) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
GHRS Initiated Coverage by Wells Fargo -- Price Target Announced at $44 - GuruFocus
GH Research PLC (GHRS) Institutional Confidence - TradingKey
Troluce Capital Advisors LLC Raises Holdings in GH Research PLC $GHRS - MarketBeat
GH Research PLC (GHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GH Research PLC (GHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):